Market Place
Sourcing Support
New Clinical Data on OPKO Health™s RAYALDEE Presented at Kidney Week 2023
02 Nov 2023 //
GLOBENEWSWIRE
OPKO Health to Present New Clinical Data on Rayaldee at Kidney Week 2023
25 Oct 2023 //
GLOBENEWSWIRE
RAYALDEE Launched in Germany by OPKO Health’s Licensee, VFMCRP
03 Feb 2022 //
GLOBENEWSWIRE
OPKO Health Announces Topline Data from Phase 2 Trial of Rayaldee
24 Dec 2021 //
TRIALSITENEWS
OPKO Health completes enrollment in phase 2 trial of Rayaldee to treat Covid-19
01 Sep 2021 //
PHARMABIZ
OPKO Health Completes Enrollment in PII Trial of RAYALDEE for COVID-19 patients
30 Aug 2021 //
GLOBENEWSWIRE
OPKO Health Initiates Clinical Trial of RAYALDEE in COVID-19 Patients
15 Sep 2020 //
BIOSPACE
FDA Authorizes OPKO Health Trial Evaluating RAYALDEE in COVID-19 Patients
02 Jun 2020 //
OPKO
OPKO receives US FDA approval to begin phase 2 trial with Rayaldee
02 Jun 2020 //
PHARMABIZ
FDA Authorizes OPKO Health Clinical Trial Evaluating RAYALDEE in COVID-19
01 Jun 2020 //
GLOBENEWSWIRE
Global Calcifediol Monohydrate Market 2020
14 Mar 2020 //
BCCOURIER
FDA to drugmakers: Don`t let manufacturing lead to rejection
05 Jan 2017 //
BIOPHARMADIVE
OPKO Announces U.S. Launch of RAYALDEE™
23 Nov 2016 //
GLOBENEWSWIRE
FDA Rejects Sanofi-Regeneron Arthritis Drug Over Plant Deficiencies
29 Oct 2016 //
WALL STREET
OPKO Health`s Calcifediol Approved in US for Secondary Hyperparathyroidism
17 Jun 2016 //
FDA
Opko Health (OPK) Falls as the FDA Halts Approval of Rayaldee
30 Mar 2016 //
BIOSPACE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.